<DOC>
	<DOCNO>NCT01692470</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness rilpivirine hydrochloride combination anti-retroviral ( ARV ) medication treatment ARV-naive ( patient expose ARV ) Filipino patient human immunodeficiency virus type 1 ( HIV-1 ) infection .</brief_summary>
	<brief_title>A Study Safety Effectiveness Rilpivirine Hydrochloride ( Edurant ) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection</brief_title>
	<detailed_description>This open-label ( people know identity study medication ) , multi-center , observational ( study investigators/ physician observe patient measure outcome ) study . The total duration study 3 year , approximately 60 patient would use rilpivirine hydrochloride routine clinical practice dose regimen stipulate product insert ( ie , 25 mg day ) enrol . As observational study , assessment patient base accepted clinical practice Philippines . Patients monitor baseline throughout 48-week ( 2nd , 4th , 8th , 12th , 24th , 36th 48th week ) treatment period rilpivirine hydrochloride .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Filipino patient ARV naive patient HIV1 infection assess physician eligible treatment ARVs Patients voluntarily sign informed consent form Patients receive drug know prolong QTc interval , medicinal product know risk Torsade de Pointes anticonvulsant , systemic dexamethasone , proton pump inhibitor Any previous treatment HIV Previously document HIV2 infection Patients viral load &gt; 100,000 HIV1 ribo nucleic acid ( RNA ) copies/ml Severely ill patient like acute acquire immune deficiency syndrome ( AIDS ) define illness major concomitant disease prior enrolment Patients severe hepatic impairment Known hypersensitivity rilpivirine hydrochloride Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Human immunodeficiency virus type 1 ( HIV-1 ) infection</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Anti-retroviral naive</keyword>
	<keyword>ARV</keyword>
	<keyword>Filipino patient</keyword>
	<keyword>Rilpivirine hydrochloride</keyword>
	<keyword>Edurant</keyword>
</DOC>